C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Cardiovascular Safety Of Extrafine Single Inhaler Triple Combination Of Beclometasone Dipropionate, Formoterol Fumarate, And Glycopyrronium Bromide In COPD: Results Of Safety Analysis From The Trilogy And Trinity Studies

• Published in: American journal of respiratory and critical care medicine Vol. 195
• Main Authors: Scuri, M, Singh, D, Papi, A, Corradi, M, Montagna, I, Francisco, C, Cohuet, G, Vezzoli, S, Muraro, A, Petruzzelli, S, Vestbo, J
• Format: Journal Article
• Language: English
• Published: New York American Thoracic Society 01-01-2017
• Subjects: Chronic obstructive pulmonary disease; Health risk assessment; Inhalers
• ISSN: 1073-449X; 1535-4970

In TRILOGY, patients were randomized (1:1) to an extrafine fixed triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; 100/6/12.5 pg, two actuations twice daily [BID] via pressurized metered dose inhaler [pMDI]; 'fixed triple') or an extrafine fixed combination of BDP/FF (100/6 pg, two actuations BID via pMDI; Foster®) (Singh et al. Conclusions: These results provide further reassurance that the additional clinical benefits of this extrafine fixed triple compared to standard treatment are not associated with a greater impact on the cardiovascular safety in severe to very severe COPD patients, further supporting its positive benefit/risk ratio.Importantly, the presence of concomitant cardiac comorbidities did not influence the rate of cardiovascular events This abstract is funded by: